Corpus ID: 29773618

Diacerein : A New Symptomatic Slow Acting Drug for Osteoarthritis

  title={Diacerein : A New Symptomatic Slow Acting Drug for Osteoarthritis},
  author={A. Mahajan and K. Singh and V. Tandon and S. Kumar and H. Kumar},
  • A. Mahajan, K. Singh, +2 authors H. Kumar
  • Published 2006
  • Medicine
  • Osteoarthritis is the most common joint disorder in world. It is one of the most frequent cause of pain, loss of function and disability in adults 2nd to Ischemic Heart Disease (IHD) (1). In India prevelence of OA has been suggested to be 24.9% (2). In one of our previous study from Jammu region it was recorded 42.4% (3). Till recently osteoarthritis was classified as a mechanical wear and tear disorder of articular cartilage for which only pain modifying therapies such as analgesics were… CONTINUE READING
    37 Citations
    Diacerein protects against iodoacetate-induced osteoarthritis in the femorotibial joints of rats
    • 7
    • PDF
    Cytochrome P450 2C9‐natural antiarthritic interactions: Evaluation of inhibition magnitude and prediction from in vitro data
    • 5
    International Journal of Medical and Biomedical Studies (IJMBS)
    • Dr. Renu Goindani, Dr. Anoop Gupta
    • 2019


    Innovative therapies in osteoarthritis
    • 13
    Osteoarthritis: epidemiology.
    • 302
    Pharmacological therapy of osteoarthritis.
    • 33
    [Diacetylrhein, a new therapeutic approach of osteoarthritis].
    • 8
    COX-1, COX-2 and articular joint disease: a role for chondroprotective agents.
    • 14
    Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group.
    • 139
    • Highly Influential
    Concomitant therapy: an outcome variable for musculoskeletal disorders? Part 2: total joint replacement in osteoarthritis trials.
    • 72
    [Mechanisms of action of diacerein, the first inhibitor of interleukin-1 in osteoarthritis].
    • 18